Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
group 3
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Peptides, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Group 3 refers to a specific treatment arm in a Phase 1 clinical trial (NCT00025857) conducted by the Centre Hospitalier Universitaire Vaudois (CHUV) for the treatment of HLA-A2 positive stage III/IV melanoma. This regimen consists of a combination of tumor-associated antigens (Melan-A/MART-1 and Tyrosinase peptides) administered with two adjuvants: the Toll-like receptor 9 (TLR-9) agonist CpG 7909 (agatolimod sodium) and the incomplete Freund's adjuvant Montanide ISA-51. The study demonstrated that the addition of CpG 7909 to the peptide/Montanide emulsion significantly enhanced the induction of antigen-specific CD8+ T cell responses compared to groups receiving fewer components. The CpG 7909 component was developed by Coley Pharmaceutical Group and later acquired by Pfizer.
- Other names
- group 3group3group-3
02
Targets
HLA-A*02:01/MART-1 (Human leukocyte antigen A*02:01 - Melanoma antigen recognized by T cells 1 complex)TCR-tyrosinase/HLA (T-cell receptor specific for tyrosinase peptide–HLA complex)HLA-A*0201-Tyr (HLA-A*0201 – tyrosinase-derived epitope)T-cell receptor specific for MART-1 peptide-HLA-A*02:01 complexTLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on group 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on group 3.